Issue: Exclusive Online Content, Posted Date: 2/3/2017

Patheon Announces Completion of its Acquisition of State-of-the-Art Manufacturing Site


Patheon N.V (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that it has completed the acquisition of a state-of-the-art manufacturing facility in Florence, South Carolina from Roche Holdings, Inc. Patheon has begun integrating the site into the Patheon network.


The site adds a 300,000 square-foot facility with manufacturing capacity for active pharmaceutical ingredient (API) ranging from development to manufacturing services. With the addition of this site, the company expands its capacity for manufacturing highly potent compounds, adds capabilities to support solid state chemistry, micronization (small & large) and future commercial spray drying.


“We are extremely pleased to add this facility to the Patheon network and the talented professionals that will support a wide range of drug substance services,” said Lukas Utiger, president of Drug Substance Services for Patheon. “Patheon has extensive experience and success integrating new sites into our global network and quickly leveraging the capabilities for the benefit of our clients.”


The new Patheon acquisition is a state-of-the-art pharmaceutical manufacturing facility. In its production space it features reactors ranging from 50-11,000 liters producing multiple products simultaneously, fully compliant to all applicable regulations, fully validated to meet the most stringent production, quality, cGMP (current Good Manufacturing Practices), safety and environmental standards. The site also provides highly flexible operations allowing the company to adapt quickly to new production needs and with capabilities in small and large scale manufacturing.


The site will serve as Patheon’s flagship U.S. API operation for commercial scale and mid-scale API production, and will also enhance Patheon’s emerging pharma presence in the U.S. market. This acquisition is the sixth in the last five years and supports the company’s plans to create the only integrated, end-to-end provider of pharma development and manufacturing services.


About Patheon

Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,000 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help clients of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. A Healthier World. Delivered.

This record has been viewed 744 times.


Click here to see the showcases

BIO Investor Forum
October 17-18, 2017
The Westin St. Francis, San Francisco, CA US
Partnership Opportunities in Drug Delivery (PODD)
October 19-20
Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Vienna, Austria

November 12-17
San Diego, CA

Pre-Filled Syringes Europe
January 17-18, 2018
Copthorne Tara Hotel, London UK

Drug Delivery Partnerships
January 22-24 Palm Beach, FL

3rd Annual Drug Development Networking Summit
March 8, 2018  Hilton Hotel Parsippany NJ
PDA Annual Meeting
March 19-21 Orlando, FL
CPhI North America
April 24-26 Philadelphia, PA 
April 17-19 New York City
RDD (Respiratory Drug Delivery)
April 22-26 Tucson, AZ
BIO 2018
June 4-7 Boston, MA
Controlled Release Society Meeting
July 23-25 New York City
Universe of Prefilled Syringes & Injection Devices
October 8-9 Orlando, FL

Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions